# Cancer Center Support Grant, Memorial Sloan Kettering Cancer Center

> **NIH NIH P30** · SLOAN-KETTERING INST CAN RESEARCH · 2021 · $59,999

## Abstract

Project Summary
This proposal is made in response to the NCI’s announcement for the Cancer Clinical Investigator Team
Leadership Award. The aim of this funding opportunity is to support mid-level clinical investigators at NCI-
designated Cancer Centers who actively enroll patients and participate in NCI-funded clinical trials in order to
promote the retention of investigators in academic clinical research careers.
This grant will be used to support my effort to expand accrual, awareness, and efficiency of early-phase clinical
trials at Memorial Sloan Kettering Cancer Center (MSKCC). Additionally, it will be used to continue and extend
my work on two NCI-sponsored clinical trials and the related correlative research. The first trial is a proof-of-
concept Phase II study evaluating EZH2 inhibition with tazemetostat in recurrent or persistent endometrioid or
clear cell ovarian cancer, and endometrioid endometrial cancer (NRG-GY014). This national NRG Oncology
protocol, for which I serve as Study Co-Chair, has an extensive biomarker analysis plan that will be led by me
and performed at MSKCC. The second trial is a Phase I study of PIK3CB inhibition with AZD8186 in
combination with docetaxel in PTEN or PIK3CB-mutated solid tumors. I am the Study Chair of this ETCTN trial
and MSKCC serves as the central site for analysis of biomarkers, including tumor sequencing (integral
biomarker), cell-free DNA sequencing, and immunohistochemistry. Both protocols exemplify my focus on
precision medicine and utilize molecular features of cancer including tumor genomics to identify predictors of
response and resistance to therapy on early-phase clinical trials. My overall goal is to improve research
efficiency at MSKCC, become an independently funded clinical researcher in academia, maximize the clinical
and biologic knowledge we gain from each trial I participate in, and ultimately improve patient care.
This proposal supports the objectives of the Center’s P30 Cancer Center Support Grant.

## Key facts

- **NIH application ID:** 10328165
- **Project number:** 3P30CA008748-55S1
- **Recipient organization:** SLOAN-KETTERING INST CAN RESEARCH
- **Principal Investigator:** CRAIG B THOMPSON
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $59,999
- **Award type:** 3
- **Project period:** 1997-01-20 → 2023-12-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10328165

## Citation

> US National Institutes of Health, RePORTER application 10328165, Cancer Center Support Grant, Memorial Sloan Kettering Cancer Center (3P30CA008748-55S1). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10328165. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*